Meet with... Sanderling Ventures

Sep 15 2016https://www.eventbrite.com/e/meet-with-sanderling-ventures-registration-26101831...

Sanderling is investing in today's seeds for tomorrow's harvest; is your technology the next bumper crop?

Since 1979, Sanderling has been dedicated to building new biomedical companies, utilizing a unique approach of specialized investment focus, active managing and long term commitment. Sanderling has supported over 90 biomedical companies from very early stage start-ups, through commercial development.

Investments are made at all stages with a focus on ground breaking early stage technologies that reduce costs in hospitals. Currently they are investing Sanderling VII which closed in 2015. Investment areas include:

  • Vaccines
  • Drug delivery
  • Research tools
  • Platform technology
  • Medical devices
  • Diagnostics
  • Imaging agents/devices
  • Digital/eHealth


Sanderling Ventures Managing Director Peter McWilliams will be in attendance to give an overview presentation about the company's key areas of interest. Following the presentation, don't miss this opportunity to introduce yourself to Peter during the networking lunch. And finally, for those companies who applied online and were approved, one-on-one meetings with Sanderling will provide an intimate forum to discuss your company.


Agenda:
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and been approved. The application period ended on August 10th.


Sanderling Ventures Participating Representative:
Peter McWilliams | Managing Director, Sanderling Ventures
Peter McWilliams is a Managing Director with Sanderling Ventures and has more than twenty years of experience in biomedical research and management. He works actively with Sanderling portfolio companies in the role of Chairman, Director, CEO and member of the management team. Portfolio companies include Actimis Pharmaceuticals (sold to Boehringer Ingelheim), Artielle Immunotherapeutics, Axikin Pharmaceuticals, Calcimedica and Liphorus Pharmaceuticals. Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin. Prior to that he was an Associate with Booz & Co (now PwC) in San Francisco where he focused on consulting projects for major US and International life science companies. Prior to that he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics, where he helped to set up and establish their US operations prior to their successful IPO on the London Stock Exchange. Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.
Connect with Peter: Connect on LinkedIn


Fees:
Presentation & Lunch
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on September 14th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on August 10th. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.


Event Partner:




About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.


Location:
The Cove @ UC Irvine
5141 California Ave. #250
Irvine, CA 92617

Share